Now showing items 1-20 of 38

    • Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer. 

      Nawaz, S; Trahearn, NA; Heindl, A; Banerjee, S; Maley, CC; Sottoriva, A; Yuan, Y (2019-10-21)
      BACKGROUND:Despite treatment advances, there remains a significant risk of recurrence in ovarian cancer, at which stage it is usually incurable. Consequently, there is a clear need for improved patient stratification. ...
    • Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. 

      Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; Rye, T; Chen, L-M; Shapira-Frommer, R; Friedlander, M; Matulonis, U; De Greve, J; Oza, AM; Banerjee, S; Molife, LR; Gore, ME; Kaye, SB; Yap, TA (2017-07)
      <h4>Background</h4>The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed ...
    • Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. 

      Winfield, JM; Wakefield, JC; Brenton, JD; AbdulJabbar, K; Savio, A; Freeman, S; Pace, E; Lutchman-Singh, K; Vroobel, KM; Yuan, Y; Banerjee, S; Porta, N; Ahmed Raza, SE; deSouza, NM (2021-01-04)
      <h4>Background</h4>Diffusion-weighted magnetic resonance imaging (DW-MRI) potentially interrogates site-specific response to neoadjuvant chemotherapy (NAC) in epithelial ovarian cancer (EOC).<h4>Methods</h4>Participants ...
    • Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. 

      George, A; Kristeleit, R; Rafii, S; Michie, CO; Bowen, R; Michalarea, V; van Hagen, T; Wong, M; Rallis, G; Molife, LR; Lopez, J; Banerji, U; Banerjee, SN; Gore, ME; de Bono, JS; Kaye, SB; Yap, TA (2017-05)
      Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug ...
    • Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. 

      Vergote, I; Banerjee, S; Gerdes, A-M; van Asperen, C; Marth, C; Vaz, F; Ray-Coquard, I; Stoppa-Lyonnet, D; Gonzalez-Martin, A; Sehouli, J; Colombo, N (2016-12)
      Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now ...
    • Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. 

      George, A; Kaye, S; Banerjee, S (2017-05)
      The treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA ...
    • Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). 

      Talhouk, A; George, J; Wang, C; Budden, T; Tan, TZ; Chiu, DS; Kommoss, S; Leong, HS; Chen, S; Intermaggio, MP; Gilks, B; Nazeran, TM; Volchek, M; Elatre, W; Bentley, RC; Senz, J; Lum, A; Chow, V; Sudderuddin, H; Mackenzie, R; Leong, SCY; Liu, G; Johnson, D; Chen, B; Group, A; Alsop, J; Banerjee, SN; Behrens, S; Bodelon, C; Brand, AH; Brinton, L; Carney, ME; Chiew, Y-E; Cushing-Haugen, KL; Cybulski, C; Ennis, D; Fereday, S; Fortner, RT; García-Donas, J; Gentry-Maharaj, A; Glasspool, R; Goranova, T; Greene, CS; Haluska, P; Harris, HR; Hendley, J; Hernandez, BY; Herpel, E; Jimenez-Linan, M; Karpinskyj, C; Kaufmann, SH; Keeney, GL; Kennedy, CJ; Köbel, M; Koziak, JM; Larson, MC; Lester, J; Lewsley, L-A; Lissowska, J; Lubiński, J; Luk, H; Macintyre, G; Mahner, S; McNeish, IA; Menkiszak, J; Nevins, N; Osorio, A; Oszurek, O; Palacios, J; Hinsley, S; Pearce, CL; Pike, MC; Piskorz, AM; Ray-Coquard, I; Rhenius, V; Rodriguez-Antona, C; Sharma, R; Sherman, ME; De Silva, D; Singh, N; Sinn, P; Slamon, D; Song, H; Steed, H; Stronach, EA; Thompson, PJ; Tołoczko, A; Trabert, B; Traficante, N; Tseng, C-C; Widschwendter, M; Wilkens, LR; Winham, SJ; Winterhoff, B; Beeghly-Fadiel, A; Benitez, J; Berchuck, A; Brenton, JD; Brown, R; Chang-Claude, J; Chenevix-Trench, G; deFazio, A; Fasching, PA; García, MJ; Gayther, SA; Goodman, MT; Gronwald, J; Henderson, MJ; Karlan, BY; Kelemen, LE; Menon, U; Orsulic, S; Pharoah, PDP; Wentzensen, N; Wu, AH; Schildkraut, JM; Rossing, MA; Konecny, GE; Huntsman, DG; Huang, RY-J; Goode, EL; Ramus, SJ; Doherty, JA; Bowtell, DD; Anglesio, MS (2020-10)
      <h4>Purpose</h4>Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, ...
    • Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. 

      Winfield, JM; Wakefield, JC; Dolling, D; Hall, M; Freeman, S; Brenton, JD; Lutchman-Singh, K; Pace, E; Priest, AN; Quest, RA; Taylor, NJ; Gabra, H; McKnight, L; Collins, DJ; Banerjee, S; Hall, E; deSouza, NM (2019-11)
      Background Treatment of advanced epithelial ovarian cancer results in a relapse rate of 75%. Early markers of response would enable optimization of management and improved outcome in both primary and recurrent disease. ...
    • An evaluation of self-perceived knowledge, attitudes and behaviours of UK oncologists about LGBTQ+ patients with cancer. 

      Berner, AM; Hughes, DJ; Tharmalingam, H; Baker, T; Heyworth, B; Banerjee, S; Saunders, D (2020-11)
      <h4>Introduction</h4>Over one million people in the UK identify as LGBTQ+ (lesbian, gay, bisexual, transgender, queer or questioning). Research has shown that this population experience differing cancer risk factors compared ...
    • Exploiting the folate receptor α in oncology. 

      Scaranti, M; Cojocaru, E; Banerjee, S; Banerji, U (2020-06)
      Folate receptor α (FRα) came into focus as an anticancer target many decades after the successful development of drugs targeting intracellular folate metabolism, such as methotrexate and pemetrexed. Binding to FRα is one ...
    • First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussion. 

      Banerjee, S; Gonzalez-Martin, A; Harter, P; Lorusso, D; Moore, KN; Oaknin, A; Ray-Coquard, I (2020-11)
      Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines ...
    • Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. 

      Yang, Y; Wu, L; Shu, X; Lu, Y; Shu, X-O; Cai, Q; Beeghly-Fadiel, A; Li, B; Ye, F; Berchuck, A; Anton-Culver, H; Banerjee, S; Benitez, J; Bjørge, L; Brenton, JD; Butzow, R; Campbell, IG; Chang-Claude, J; Chen, K; Cook, LS; Cramer, DW; deFazio, A; Dennis, J; Doherty, JA; Dörk, T; Eccles, DM; Edwards, DV; Fasching, PA; Fortner, RT; Gayther, SA; Giles, GG; Glasspool, RM; Goode, EL; Goodman, MT; Gronwald, J; Harris, HR; Heitz, F; Hildebrandt, MA; Høgdall, E; Høgdall, CK; Huntsman, DG; Kar, SP; Karlan, BY; Kelemen, LE; Kiemeney, LA; Kjaer, SK; Koushik, A; Lambrechts, D; Le, ND; Levine, DA; Massuger, LF; Matsuo, K; May, T; McNeish, IA; Menon, U; Modugno, F; Monteiro, AN; Moorman, PG; Moysich, KB; Ness, RB; Nevanlinna, H; Olsson, H; Onland-Moret, NC; Park, SK; Paul, J; Pearce, CL; Pejovic, T; Phelan, CM; Pike, MC; Ramus, SJ; Riboli, E; Rodriguez-Antona, C; Romieu, I; Sandler, DP; Schildkraut, JM; Setiawan, VW; Shan, K; Siddiqui, N; Sieh, W; Stampfer, MJ; Sutphen, R; Swerdlow, AJ; Szafron, LM; Teo, SH; Tworoger, SS; Tyrer, JP; Webb, PM; Wentzensen, N; White, E; Willett, WC; Wolk, A; Woo, YL; Wu, AH; Yan, L; Yannoukakos, D; Chenevix-Trench, G; Sellers, TA; Pharoah, PDP; Zheng, W; Long, J (2019-02)
      DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains ...
    • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. 

      Capoluongo, E; Ellison, G; López-Guerrero, JA; Penault-Llorca, F; Ligtenberg, MJL; Banerjee, S; Singer, C; Friedman, E; Markiefka, B; Schirmacher, P; Büttner, R; van Asperen, CJ; Ray-Coquard, I; Endris, V; Kamel-Reid, S; Percival, N; Bryce, J; Röthlisberger, B; Soong, R; de Castro, DG (2017-06)
      The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 ...
    • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 

      Phelan, CM; Kuchenbaecker, KB; Tyrer, JP; Kar, SP; Lawrenson, K; Winham, SJ; Dennis, J; Pirie, A; Riggan, MJ; Chornokur, G; Earp, MA; Lyra, PC; Lee, JM; Coetzee, S; Beesley, J; McGuffog, L; Soucy, P; Dicks, E; Lee, A; Barrowdale, D; Lecarpentier, J; Leslie, G; Aalfs, CM; Aben, KKH; Adams, M; Adlard, J; Andrulis, IL; Anton-Culver, H; Antonenkova, N; AOCS study group; Aravantinos, G; Arnold, N; Arun, BK; Arver, B; Azzollini, J; Balmaña, J; Banerjee, SN; Barjhoux, L; Barkardottir, RB; Bean, Y; Beckmann, MW; Beeghly-Fadiel, A; Benitez, J; Bermisheva, M; Bernardini, MQ; Birrer, MJ; Bjorge, L; Black, A; Blankstein, K; Blok, MJ; Bodelon, C; Bogdanova, N; Bojesen, A; Bonanni, B; Borg, Å; Bradbury, AR; Brenton, JD; Brewer, C; Brinton, L; Broberg, P; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Buecher, B; Butzow, R; Buys, SS; Caldes, T; Caligo, MA; Campbell, I; Cannioto, R; Carney, ME; Cescon, T; Chan, SB; Chang-Claude, J; Chanock, S; Chen, XQ; Chiew, Y-E; Chiquette, J; Chung, WK; Claes, KBM; Conner, T; Cook, LS; Cook, J; Cramer, DW; Cunningham, JM; D'Aloisio, AA; Daly, MB; Damiola, F; Damirovna, SD; Dansonka-Mieszkowska, A; Dao, F; Davidson, R; DeFazio, A; Delnatte, C; Doheny, KF; Diez, O; Ding, YC; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Dossus, L; Duran, M; Dürst, M; Dworniczak, B; Eccles, D; Edwards, T; Eeles, R; Eilber, U; Ejlertsen, B; Ekici, AB; Ellis, S; Elvira, M; EMBRACE Study; Eng, KH; Engel, C; Evans, DG; Fasching, PA; Ferguson, S; Ferrer, SF; Flanagan, JM; Fogarty, ZC; Fortner, RT; Fostira, F; Foulkes, WD; Fountzilas, G; Fridley, BL; Friebel, TM; Friedman, E; Frost, D; Ganz, PA; Garber, J; García, MJ; Garcia-Barberan, V; Gehrig, A; GEMO Study Collaborators; Gentry-Maharaj, A; Gerdes, A-M; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goldgar, DE; Goranova, T; Gore, M; Greene, MH; Gronwald, J; Gruber, S; Hahnen, E; Haiman, CA; Håkansson, N; Hamann, U; Hansen, TVO; Harrington, PA; Harris, HR; Hauke, J; HEBON Study; Hein, A; Henderson, A; Hildebrandt, MAT; Hillemanns, P; Hodgson, S; Høgdall, CK; Høgdall, E; Hogervorst, FBL; Holland, H; Hooning, MJ; Hosking, K; Huang, R-Y; Hulick, PJ; Hung, J; Hunter, DJ; Huntsman, DG; Huzarski, T; Imyanitov, EN; Isaacs, C; Iversen, ES; Izatt, L; Izquierdo, A; Jakubowska, A; James, P; Janavicius, R; Jernetz, M; Jensen, A; Jensen, UB; John, EM; Johnatty, S; Jones, ME; Kannisto, P; Karlan, BY; Karnezis, A; Kast, K; KConFab Investigators; Kennedy, CJ; Khusnutdinova, E; Kiemeney, LA; Kiiski, JI; Kim, S-W; Kjaer, SK; Köbel, M; Kopperud, RK; Kruse, TA; Kupryjanczyk, J; Kwong, A; Laitman, Y; Lambrechts, D; Larrañaga, N; Larson, MC; Lazaro, C; Le, ND; Le Marchand, L; Lee, JW; Lele, SB; Leminen, A; Leroux, D; Lester, J; Lesueur, F; Levine, DA; Liang, D; Liebrich, C; Lilyquist, J; Lipworth, L; Lissowska, J; Lu, KH; Lubinński, J; Luccarini, C; Lundvall, L; Mai, PL; Mendoza-Fandiño, G; Manoukian, S; Massuger, LFAG; May, T; Mazoyer, S; McAlpine, JN; McGuire, V; McLaughlin, JR; McNeish, I; Meijers-Heijboer, H; Meindl, A; Menon, U; Mensenkamp, AR; Merritt, MA; Milne, RL; Mitchell, G; Modugno, F; Moes-Sosnowska, J; Moffitt, M; Montagna, M; Moysich, KB; Mulligan, AM; Musinsky, J; Nathanson, KL; Nedergaard, L; Ness, RB; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Nussbaum, RL; Odunsi, K; Olah, E; Olopade, OI; Olsson, H; Olswold, C; O'Malley, DM; Ong, K-R; Onland-Moret, NC; OPAL study group; Orr, N; Orsulic, S; Osorio, A; Palli, D; Papi, L; Park-Simon, T-W; Paul, J; Pearce, CL; Pedersen, IS; Peeters, PHM; Peissel, B; Peixoto, A; Pejovic, T; Pelttari, LM; Permuth, JB; Peterlongo, P; Pezzani, L; Pfeiler, G; Phillips, K-A; Piedmonte, M; Pike, MC; Piskorz, AM; Poblete, SR; Pocza, T; Poole, EM; Poppe, B; Porteous, ME; Prieur, F; Prokofyeva, D; Pugh, E; Pujana, MA; Pujol, P; Radice, P; Rantala, J; Rappaport-Fuerhauser, C; Rennert, G; Rhiem, K; Rice, P; Richardson, A; Robson, M; Rodriguez, GC; Rodríguez-Antona, C; Romm, J; Rookus, MA; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, IB; Salvesen, HB; Sandler, DP; Schoemaker, MJ; Senter, L; Setiawan, VW; Severi, G; Sharma, P; Shelford, T; Siddiqui, N; Side, LE; Sieh, W; Singer, CF; Sobol, H; Song, H; Southey, MC; Spurdle, AB; Stadler, Z; Steinemann, D; Stoppa-Lyonnet, D; Sucheston-Campbell, LE; Sukiennicki, G; Sutphen, R; Sutter, C; Swerdlow, AJ; Szabo, CI; Szafron, L; Tan, YY; Taylor, JA; Tea, M-K; Teixeira, MR; Teo, S-H; Terry, KL; Thompson, PJ; Thomsen, LCV; Thull, DL; Tihomirova, L; Tinker, AV; Tischkowitz, M; Tognazzo, S; Toland, AE; Tone, A; Trabert, B; Travis, RC; Trichopoulou, A; Tung, N; Tworoger, SS; van Altena, AM; Van Den Berg, D; van der Hout, AH; van der Luijt, RB; Van Heetvelde, M; Van Nieuwenhuysen, E; van Rensburg, EJ; Vanderstichele, A; Varon-Mateeva, R; Vega, A; Edwards, DV; Vergote, I; Vierkant, RA; Vijai, J; Vratimos, A; Walker, L; Walsh, C; Wand, D; Wang-Gohrke, S; Wappenschmidt, B; Webb, PM; Weinberg, CR; Weitzel, JN; Wentzensen, N; Whittemore, AS; Wijnen, JT; Wilkens, LR; Wolk, A; Woo, M; Wu, X; Wu, AH; Yang, H; Yannoukakos, D; Ziogas, A; Zorn, KK; Narod, SA; Easton, DF; Amos, CI; Schildkraut, JM; Ramus, SJ; Ottini, L; Goodman, MT; Park, SK; Kelemen, LE; Risch, HA; Thomassen, M; Offit, K; Simard, J; Schmutzler, RK; Hazelett, D; Monteiro, AN; Couch, FJ; Berchuck, A; Chenevix-Trench, G; Goode, EL; Sellers, TA; Gayther, SA; Antoniou, AC; Pharoah, PDP (2017-05)
      To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified ...
    • Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. 

      Chazan, G; Franchini, F; Alexander, M; Banerjee, S; Mileshkin, L; Blinman, P; Zielinski, R; Karikios, D; Pavlakis, N; Peters, S; Lordick, F; Ball, D; Wright, G; IJzerman, M; Solomon, B (2020-12)
      <b>Objectives: </b>To report clinician-perceived changes to cancer service delivery in response to COVID-19.<br><br><b>Design: </b>Multidisciplinary Australasian cancer clinician survey in collaboration with the European ...
    • The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. 

      McLachlan, J; Boussios, S; Okines, A; Glaessgen, D; Bodlar, S; Kalaitzaki, R; Taylor, A; Lalondrelle, S; Gore, M; Kaye, S; Banerjee, S (2017-03)
      <h4>Aims</h4>Despite recent advances in the primary and secondary prevention of cervical cancer, a significant number of women present with or develop metastatic disease. There is currently no consensus on the standard of ...
    • Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. 

      George, A; Riddell, D; Seal, S; Talukdar, S; Mahamdallie, S; Ruark, E; Cloke, V; Slade, I; Kemp, Z; Gore, M; Strydom, A; Banerjee, S; Hanson, H; Rahman, N (2016-07-13)
      Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing ...
    • Improving outcomes for older women with gynaecological malignancies. 

      Dumas, L; Ring, A; Butler, J; Kalsi, T; Harari, D; Banerjee, S (2016-11)
      The incidence of most gynaecological malignancies rises significantly with increasing age. With an ageing population, the proportion of women over the age of 65 with cancer is expected to rise substantially over the next ...
    • Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. 

      Dolly, SO; Migali, C; Tunariu, N; Della-Pepa, C; Khakoo, S; Hazell, S; de Bono, JS; Kaye, SB; Banerjee, S (2017-01)
      Peritoneal mesothelioma (MPeM) is a scarce abdominal-pelvic malignancy that presents with non-specific features and exhibits a wide clinical spectrum from indolent to aggressive disease. Due to it being a rare entity, there ...